PE20050862A1 - Derivados de indano heterociclicos sustituidos como antagonistas de los receptores de dopamina d2 y serotonina 2a - Google Patents

Derivados de indano heterociclicos sustituidos como antagonistas de los receptores de dopamina d2 y serotonina 2a

Info

Publication number
PE20050862A1
PE20050862A1 PE2004001197A PE2004001197A PE20050862A1 PE 20050862 A1 PE20050862 A1 PE 20050862A1 PE 2004001197 A PE2004001197 A PE 2004001197A PE 2004001197 A PE2004001197 A PE 2004001197A PE 20050862 A1 PE20050862 A1 PE 20050862A1
Authority
PE
Peru
Prior art keywords
alkyl
receptors
heterocyclic
innane
serotonin
Prior art date
Application number
PE2004001197A
Other languages
English (en)
Inventor
Dejian Xie
James Michael Graham
Brian Edward Kornberg
Sham Shridhar Nikam
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34811295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050862(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20050862A1 publication Critical patent/PE20050862A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE INDANO HETEROCICLICOS SUSTITUIDOS DE FORMULA IA DONDE J ES S, SO,SO2, CH2, NR10 DONDE R10 ES H, ALQUILO C1-C6, C(=O)ALQUILO C1-C6, C(=O)O-ALQULO C1-C6; M ES CH, N; G ES CH, N; m ES 1 A 6; X ES O, NR3, DONDE R3 ES R10, C(=O), CHOH, CHOR3, ENTRE OTROS; R1 ES H, HALO, CIANO, ALQUILO C1-C6 SUSTITUIDO CON UNO A TRES ATOMOS DE FLUOR, ALCOXI C1-C6 OPCIONALMENTE SUSTITUIDO CON UNO A TRES ATOMOS DE FLUOR,ENTRE OTROS; R2 ES R1 CON LA CONDICION DE QUE R2 NO PUEDE FORMAR UN ANILLO HETEROCICLICO CUANDO ESTA PRESENTE R1; R4 Y R5 SON H, HALO, CIANO, AMINOALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS; R6, R7, R8 Y R9 SON H, ALQUILO C1-C6, OPCIONALMENTE SUSTITUIDO CON UNO A TRES ATOMOS DE FLUOR; Y CUANDO R11 ESTA PRESENTE SE SELECCIONA DE O, NR13, EN EL QUE R13 SE DEFINE COMO R10, (CH2)w DONDE w ES 1 A 6; n ES 1 A 3; z ES 1 A 3; R11 ES H, ALQUILO C1-C6, -SO2-ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS N-{6-[2(4-BENZO[d]ISOTIAZOL-3-ILPIPERAZIN-1-IL)ETIL]INDAN-1-IL}ACETAMIDA; (S)(+)-N-{5-[2-(4-BENZO[d]ISOTIAZOL-3-ILPIPERAZIN-1-IL)ETIL]INDAN-2-IL}ACETAMIDA; (R)(-)-N-{5-[2-(4-BENZO[d]ISOTIAZOL-3-ILPIPERAZIN-1-IL)ETIL]INDAN-2-IL}PROPIONAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO PARA LA PREPARACION. DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES DE DOPAMINA D2 Y DE LOS RECEPTORES DE SEROTONINAS 2A (5HT2A) SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA Y OTRAS AFECCIONES DEL SNC
PE2004001197A 2003-12-08 2004-12-06 Derivados de indano heterociclicos sustituidos como antagonistas de los receptores de dopamina d2 y serotonina 2a PE20050862A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52785203P 2003-12-08 2003-12-08
US53109603P 2003-12-19 2003-12-19

Publications (1)

Publication Number Publication Date
PE20050862A1 true PE20050862A1 (es) 2005-12-17

Family

ID=34811295

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001197A PE20050862A1 (es) 2003-12-08 2004-12-06 Derivados de indano heterociclicos sustituidos como antagonistas de los receptores de dopamina d2 y serotonina 2a

Country Status (12)

Country Link
US (1) US20050282819A1 (es)
EP (1) EP1697334A1 (es)
JP (1) JP2007513197A (es)
AR (1) AR047325A1 (es)
BR (1) BRPI0416739A (es)
CA (1) CA2548447A1 (es)
NL (1) NL1027680C2 (es)
PA (1) PA8619301A1 (es)
PE (1) PE20050862A1 (es)
TW (1) TW200524922A (es)
UY (1) UY28656A1 (es)
WO (1) WO2005056540A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
WO2007076601A1 (en) * 2006-01-03 2007-07-12 Clera Inc. Imaging of d2high receptors using radiolabelled (-)- quinpirole and analogs thereof
TW200804347A (en) 2006-01-10 2008-01-16 Janssen Pharmaceutica Nv Urotensin II receptor antagonists
JP2009533325A (ja) * 2006-03-17 2009-09-17 アストラゼネカ・アクチエボラーグ 5−ht6調節剤としての新規なテトラリン
AU2007281591A1 (en) 2006-07-31 2008-02-07 Janssen Pharmaceutica, N.V. Urotensin II receptor antagonists
ATE546448T1 (de) * 2008-08-02 2012-03-15 Janssen Pharmaceutica Nv Urotensin-ii-rezeptorantagonisten
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
AR075401A1 (es) * 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
CN104140421B (zh) * 2013-05-08 2017-04-05 上海医药工业研究院 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2671350A1 (fr) * 1991-01-08 1992-07-10 Adir Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
US6242450B1 (en) * 1998-07-27 2001-06-05 Eli Lilly And Company 5-HT1F antagonists
CA2716369C (en) * 1999-05-24 2013-05-14 Mitsubishi Tanabe Pharma Corporation Phenoxypropylamine compounds
WO2001017993A1 (en) * 1999-09-09 2001-03-15 EGIS Gyógyszergyár Rt. Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient
WO2004026864A1 (en) * 2002-09-17 2004-04-01 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004029048A1 (en) * 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia

Also Published As

Publication number Publication date
NL1027680A1 (nl) 2005-06-09
US20050282819A1 (en) 2005-12-22
CA2548447A1 (en) 2005-06-23
PA8619301A1 (es) 2005-11-25
AR047325A1 (es) 2006-01-18
TW200524922A (en) 2005-08-01
UY28656A1 (es) 2005-07-29
WO2005056540A1 (en) 2005-06-23
NL1027680C2 (nl) 2005-11-30
BRPI0416739A (pt) 2007-01-16
JP2007513197A (ja) 2007-05-24
EP1697334A1 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
PE20010600A1 (es) Derivados de bencimidazolonas que tienen afinidad para receptores mezclados de serotonina y dopamina
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20060988A1 (es) Sintesis asimetrica de dihidrobenzofuranos sustituidos
PE20080889A1 (es) Aminometil-4-imidazoles
AR056103A1 (es) Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1
PE20020510A1 (es) DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20020735A1 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b
PE20060878A1 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
PE20020540A1 (es) Derivados del acido benzo pirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos
AR055171A1 (es) Derivados de carboxamida como antagonistas del receptor muscarinico
PE20020063A1 (es) Bis-arilsulfonas como ligandos del receptor de 5-ht
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20071022A1 (es) Compuestos derivados de dibencilamina como inhibidores de la proteina de transferencia del colesteril ester (cept)
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20050862A1 (es) Derivados de indano heterociclicos sustituidos como antagonistas de los receptores de dopamina d2 y serotonina 2a
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20030610A1 (es) Derivados de 3-azabiciclo[3.1.0]hexano con afinidad a los receptores opioides

Legal Events

Date Code Title Description
FA Abandonment or withdrawal